RIGL

Rigel Pharmaceuticals Stock Price

3.39
0.13 (3.99%)
Upgrade to Real-Time
Afterhours (Closed)
3.39

Low
1.71

52 Week Range

High
5.50

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Rigel Pharmaceuticals Inc RIGL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.13 3.99% 3.39 19:43:14
Open Price Low Price High Price Close Price Prev Close
3.33 3.29 3.43 3.38 3.26
Bid Price Ask Price Spread News
3.35 3.42 0.07 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
8,296 1,706,054 $ 3.38 $ 5,769,693 2,933,958 1.71 - 5.50
Last Trade Time Type Quantity Stock Price Currency
19:44:09 8 $ 3.42 USD

Rigel Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 576.71M 170.12M 130.84M $ 108.62M $ -104.78M -0.17 -21.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 0.40%

more financials information »

Rigel Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RIGL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.633.783.203.481,957,937-0.24-6.61%
1 Month3.303.973.073.593,305,4000.092.73%
3 Months4.495.503.073.953,638,928-1.10-24.5%
6 Months2.495.502.483.783,221,3650.9036.14%
1 Year1.835.501.713.374,151,2411.5685.25%
3 Years3.905.501.232.992,546,104-0.51-13.08%
5 Years2.315.501.233.092,115,3591.0846.75%

Rigel Pharmaceuticals Description

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.


Your Recent History
NASDAQ
RIGL
Rigel Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.